Moreover, the percentage of Treg (CD4+, CD25+, FoxP3+), which is associated with a poor prognosis,34,35 was not altered by KLS-3010, while effector T cells (Teff; CD8+ IFF-γ+, and CD4+ IFF-γ+) were significantly increased among tumor-infiltrating lymphocytes in KLS-3010-treated mice (Fig. 5). This evidence concerns the gene RPS6KB2 and neoplasm.